Condition: Lymphoma · CLL · Acute Lymphoblastic Leukemia, Pediatric · Sponsor: University Hospital Tuebingen
A Phase I dose finding study of MB-CART2219.1 targeting CD19/CD22 in adult and pediatric patients with relapsed/refractory B-cell malignancies
This description comes directly from the study's public registry record.
Wolfgang Bethge, Prof. Dr. · +49 7071 29-83176 · Wolfgang.Bethge@med.uni-tuebingen.de
Peter Lang, Prof. Dr. · +49 7071 29-80894 · Peter.Lang@med.uni-tuebingen.de
Always discuss trial participation with your own doctor first.
| University Hospital , Department of Internal Medicine II | Tübingen, Baden-Wurttemberg, Germany | Recruiting |
| University Hospital, Clinic for Pediatric Medicine | Tübingen, Baden-Wurttemberg, Germany | Not Yet Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07108868